Overview

A Multicenter Clinical Study Evaluating the Clinical Outcomes of HR+/HER2- Advanced Breast Cancer With Different HER2 Expression Levels in Combination With a Real-world CDK4/6 Inhibitor Combined With Endocrine Therapy

Status:
Not yet recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
By retrospectively collecting and arranging real-world data of multi-center HR+/HER2- advanced breast cancer in China combined with CDK4/6 inhibitor and endocrine therapy, we analyzed different HER2 expression levels (HER2 0, 1+, 2+ and FISH-), especially Clinical outcomes of endocrine therapy for metastatic breast cancer with low HER2 expression (HER2 1+, 2+ and FISH-), exploring potential biomarkers of CDK4/6 inhibitors, and understanding the outcome characteristics of HER2 heterogeneity in MBC through multivariate analysis , and guide clinical application.
Phase:
N/A
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital